share_log

Molecular Partners Presents Interim Safety And Mechanistic Data From Ongoing Phase 1 Trial Of MP0317 For Treatment of Solid Tumors

Molecular Partners Presents Interim Safety And Mechanistic Data From Ongoing Phase 1 Trial Of MP0317 For Treatment of Solid Tumors

分子伙伴公司提供正在进行的MP0317治疗实体肿瘤第一阶段试验的临时安全性和机械学数据
Benzinga Real-time News ·  2022/11/10 01:42
First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents Dose escalation remains ongoing with study recruitment anticipated to complete in 1H 2023
MP0317提供肿瘤局部CD40激活的首次临床观察 没有观察到系统性或剂量限制性毒性,这是CD40药物的关键参数 剂量递增仍在进行中,研究招募预计将于2023年上半年完成
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of positive interim results from the ongoing Phase 1 trial of the company's MP0317 (FAP X CD40) program for the treatment of solid tumors at...
瑞士苏黎世-施利伦和马萨诸塞州康科德,2022年11月10日(Global Newswire)--根据第53条特别宣布:分子伙伴公司((...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发